The role of neoantigens in tumor immunotherapy

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Tumor neoantigens are aberrant polypeptides arising from genomic mutations in cancer cells.
• Neoantigens are highly immunogenic and specific to tumors, distinguishing them from tumor-related antigens and avoiding autoimmunity.
• Advances in bioinformatics and sequencing technologies are driving progress in neoantigen-based cancer immunotherapy.

Purpose of the Study:

• To review the generation, prediction, and identification of novel tumor neoantigens.
• To outline and compare mechanisms of Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy and immune checkpoint blockade therapy.
• To discuss the application of neoantigens in CAR-T and PD-1/PD-L1 blockade therapies and summarize the benefits of neoantigen vaccines.

Main Methods:

• Review of current literature on neoantigen generation, prediction, and identification.
• Comparative analysis of CAR-T therapy and immune checkpoint blockade mechanisms.
• Exploration of neoantigen applications in advanced cancer immunotherapies.

Main Results:

• Neoantigens offer a promising avenue for personalized cancer treatment due to their high immunogenicity and tumor specificity.
• CAR-T therapy and immune checkpoint blockade (e.g., PD-1/PD-L1) are key modalities leveraging neoantigens.
• Neoantigen vaccines demonstrate potential advantages over conventional vaccines in eliciting anti-tumor immune responses.

Conclusions:

• Neoantigen-based therapies, including personalized vaccines, CAR-T, and immune checkpoint inhibitors, represent a significant advancement in cancer immunotherapy.
• The integration of bioinformatics and sequencing is crucial for effective neoantigen discovery and application.
• Future prospects for neoantigen therapy are bright, offering hope for more effective and targeted cancer treatments.